September 30, 2020 07:38 AM EDT
R&D
FDA+

Dis­trict Court throws out Cat­a­lyst law­suit al­leg­ing im­prop­er ap­proval stan­dards for ri­val LEMS drug

Max Gelman

Senior Editor

Cat­a­lyst Phar­ma­ceu­ti­cals re­ceived bad news Tues­day af­ter­noon as a fed­er­al judge threw out their law­suit ac­cus­ing the FDA of il­le­gal­ly ap­prov­ing a ri­val drug …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

A service from the Financial Times